EP0678095A1 — Crystalline penicillin derivative, and its production and use
Assigned to Taiho Pharmaceutical Co Ltd · Expires 1995-10-25 · 31y expired
What this patent protects
Crystalline sodium 2α-methyl-2β-(1,2,3-triazol-1-yl)-methylpenam-3α-carboxylate-1,1-dioxide monohydrate (crystalline tazobactam sodium monohydrate) obtainable by adding to a concentrated aqueous solution of sodium 2α-methyl-2β-(1,2,3-triazol-1-yl)-methylpenam-3α-carboxylate-1,1-d…
USPTO Abstract
Crystalline sodium 2α-methyl-2β-(1,2,3-triazol-1-yl)-methylpenam-3α-carboxylate-1,1-dioxide monohydrate (crystalline tazobactam sodium monohydrate) obtainable by adding to a concentrated aqueous solution of sodium 2α-methyl-2β-(1,2,3-triazol-1-yl)-methylpenam-3α-carboxylate-1,1-dioxide (tazobactam sodium) a solvent selected from acetone and ethanol in an amount corresponding to a solvent to water ratio of between about 95:5 and 99:1 v/v and crystallizing the desired product from the solvent mixture. The crystalline tazobactam sodium monohydrate exhibits a high β-lactamase inhibitory activity in combination with β-lactam antibiotics.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.